| Followers | 1440 |
| Posts | 30193 |
| Boards Moderated | 24 |
| Alias Born | 12/10/2012 |
Monday, November 03, 2025 3:38:19 PM
$PRLD: Definitely surging here EOD...... now $3.25
SO whats the news............... or are they just catching up to that its been dwinddling.
Interesting to see if this holds up.
GO $PRLD
SO whats the news............... or are they just catching up to that its been dwinddling.
Interesting to see if this holds up.
GO $PRLD
Recent PRLD News
- Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering • GlobeNewswire Inc. • 04/20/2026 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 10:16:38 AM
- Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 11:41:22 AM
- Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 11:39:30 PM
- Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 03/17/2026 08:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:18:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/12/2026 08:16:15 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/10/2026 12:40:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/10/2026 12:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 12:17:31 PM
- Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 • GlobeNewswire Inc. • 03/10/2026 11:01:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:02:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:14:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:11:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:10:06 PM
- The $71 Billion Cancer Shift: Why The FDA Is Speeding Up • GlobeNewswire Inc. • 02/05/2026 02:26:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 02:11:26 PM
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor • GlobeNewswire Inc. • 02/03/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2026 12:30:29 PM
- Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards • GlobeNewswire Inc. • 12/16/2025 05:18:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/10/2025 09:06:28 PM
